Therapy wins rare pediatric disease designation for hard-to-treat glioma
The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to iopofosine I 131 — now being tested in young people in…
Glioma
Advocates urge action after NICE rejects Voranigo for England’s NHS
In a setback for brain tumor patients, England’s National Health Service (NHS) has been advised not to routinely cover the new cancer therapy Voranigo…
New treatment leads to longer survival for glioblastoma patients
In a small clinical trial involving individuals with recurrent glioblastoma — a highly aggressive form of glioma — patients who received a single injection…
FDA grants orphan drug designation to glioblastoma treatment
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to an experimental therapy called cintredekin besudotox (IL13-PE38QQR), which Precision Neuromed is…
Iopofosine I 131 may improve survival in pediatric brain cancer
The experimental therapy iopofosine I 131Â may improve survival outcomes in children and young adults with hard-to-treat glioma, according to new clinical trial data announced…
Voranigo becomes 1st therapy in EU to target IDH-mutated glioma
The European Commission has approved Voranigo (vorasidenib) for certain types of glioma, marking the arrival of a new targeted pill poised to change…
Clinical trial testing BPM31510 for glioblastoma now fully enrolled
Enrollment is now complete in a Phase 2b clinical trial testing Bpgbio’s BPM31510, a treatment candidate for glioblastoma multiforme (GBM), a rapidly progressing type…
Modeyso added to NCCN guidelines for rare brain cancer
The National Comprehensive Cancer Network (NCCN) has updated its clinical practice guidelines to include Modeyso (dordaviprone) as an appropriate option for a rare recurrent…
New strategy targets the ‘mesh’ around tumors to stop glioblastoma
Researchers may have found a way to halt the spread of aggressive brain tumors by targeting the environment around the cancer cells. A new study…
Patients needed for trial of CUE-102 for hard-to-treat glioblastoma
Enrollment is now open in a U.S. clinical trial testing the immune-modulating therapy CUE-102 in people with recurrent glioblastoma, an aggressive form of glioma…
